• The future of Pfizer’s $5bn Lyrica brand is in jeopardy pharmaceutical-technology
    November 22, 2018
    Lyrica (pregabalin) has been Pfizer’s flagship blockbuster brand for many years due to the fact that it has been approved in multiple indications. It has also been the highest-selling neurology brand for several years.
PharmaSources Customer Service